Merck and Company: Vioxx

Merck and enunciate recently pulled its arthritis medication, rofecoxib, off the shelves because of recent studies that link the do drugs to increased risk of heart attack and stroke. The FDA had been conducting a theater that showed an increased amount of cardiovascular problems in those who had been using rofecoxib for eighteen months or more. This decision has divulgeraged mevery rofecoxib users because many had no idea of the newfound risks associated with rofecoxib. Although rofecoxib users did non know of the increased risks of the product, they were aw ar of the potential side do such as abnormal abdominal pain and flu-like symptoms. rofecoxib is one example of a drug that was not adequately tested by the FDA and as a result endue longtime users at risk of attracting potenti anyy fatal symptoms. two the FDA and Merck and alliance have been blamed for not researching the drug enough, only when Merck and Company was only the manucircumstanceurer. The FDA review s and tests all drugs before putting them out on the open market and therefore deserves most of the blame. The FDA allowed Vioxx to be put on the market in 1999 and deep down the low gear two years there were tests through with(p) by the FDA on Vioxx after complaints about bear pains but the studies done did not reveal any major risks associated with Vioxx.

The scare part about this story is that the look at done that observed these increased risks was intended to determine whether or not Vioxx protected against cancerous intestinal polyps or extra tissue. The fact that the FDA came across this information on incident shows the public how bestial t! he FDA was on the subject of risks associated with Vioxx. Many, if not all Vioxx users are stunned that the FDA did not take complaints poorly about side... If you emergency to get a full essay, order it on our website: OrderCustomPaper.com

If you want to get a full essay, visit our page: write my paper